Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
What is your preferred duration of aggrastat therapy, and does it differ if patient presented with NSTEMI versus STEMI?
Related Questions
Is there any difference between colchicine 0.5mg vs 0.6 mg for high risk coronary artery disease?
Would you continue SAPT beyond 12 months after left main stenting in an elderly patient on DOAC for paroxysmal atrial fibrillation?
What are your preferred guide catheters to use for engaging coronaries in patients with mechanical or bioprosthetic aortic valves?
What advice would you give to patients with refractory nausea and vomiting at home who are unable to take oral medications but have recently had a PCI and stent placement requiring uninterrupted DAPT?
When do you consider revascularizing chronic total occlusions after failing medical management?
During a coronary intervention, if the activated clotting time (ACT) is not within the therapeutic range despite administering weight-based unfractionated heparin, what alternative options do you consider?
What is your stepwise approach to managing no re-flow during PCI?
What is your preferred P2Y12 inhibitor to use upstream of STEMI cases, if you decide to administer an agent before proceeding to the cath lab?
What has been your experience with Coronary CTA with FFR results and its ability to accurately predict epicardial CAD on diagnostic LHC?
Do you recommend stepwise de-escalation of dual antiplatelet therapy for patients at high risk of bleeding who have undergone drug-coated balloon angioplasty?
